R. Ray

发表

Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial

R. Abrams, C. Hurt, J. Staffurth, 2013, The Lancet. Oncology.

Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial.

C. Hurt, D. Cunningham, J. Staffurth, 2013, The Lancet. Oncology.

Prospective review of radiotherapy trials through implementation of standardized multicentre workflow and IT infrastructure.

D. Eaton, J. Staffurth, E. Miles, 2016, The British journal of radiology.

Patient-reported outcomes during and after definitive chemoradiotherapy for oesophageal cancer

C. Hurt, D. Cunningham, J. Bridgewater, 2015, British Journal of Cancer.

NEOSCOPE: A randomised phase II study of induction chemotherapy followed by oxaliplatin/capecitabine or carboplatin/paclitaxel based pre-operative chemoradiation for resectable oesophageal adenocarcinoma

H. Grabsch, C. Hurt, Ricky A. Sharma, 2017, European journal of cancer.

Use of perioperative prophylactic antibiotics following excision of ulcerated skin lesions in the UK: a national, multispeciality survey of clinicians

R. Matin, E. Thomas-Jones, R. Ray, 2021, Clinical and experimental dermatology.

A prospective phase II study of pre-operative chemotherapy then short-course radiotherapy for high risk rectal cancer: COPERNICUS

C. Hurt, P. Quirke, G. Griffiths, 2018, British Journal of Cancer.

Long-term results and recurrence patterns from SCOPE-1: a phase II/III randomised trial of definitive chemoradiotherapy +/− cetuximab in oesophageal cancer

C. Hurt, D. Cunningham, J. Staffurth, 2017, British Journal of Cancer.

Long-term results and recurrence patterns from SCALOP: a phase II randomised trial of gemcitabine- or capecitabine-based chemoradiation for locally advanced pancreatic cancer

R. Abrams, C. Hurt, J. Staffurth, 2017, British Journal of Cancer.

Long term results and patterns of recurrence from SCOPE 1: A phase II/III randomised trial of definitive chemoradiotherapy (dCRT) plus or minus cetuximab (dCRT plus C) in esophageal cancer

C. Hurt, D. Cunningham, J. Staffurth, 2016 .

Oxaliplatin/capecitabine or carboplatin/paclitaxel-based preoperative chemoradiation for resectable oesophageal adenocarcinoma (NeoSCOPE): Long-term results of a randomised controlled trial

H. Grabsch, Ricky A. Sharma, T. Crosby, 2021, European journal of cancer.

Induction oxaliplatin capecitabine followed by switch to carboplatin-paclitaxel based RT versus continuing oxaliplatin capecitabine RT in operable esophageal adenocarcinoma: Survival analysis of the randomized phase II neoscope trial.

H. Grabsch, C. Hurt, Ricky A. Sharma, 2020 .

On-trial radiotherapy quality assurance in NeoSCOPE: A randomised phase II trial of chemoradiotherapy in oesophageal cancer.

T. Crosby, M. Hawkins, S. Mukherjee, 2016 .

Esophageal Delineation - Lessons Learned From Pre-Accrual Benchmark Cases in the UK NeoSCOPE Esophageal Trial

E. Miles, E. Spezi, T. Crosby, 2014 .

Prospective Review of Outlining in the UK NeoSCOPE Esophageal Trial

E. Miles, E. Spezi, T. Crosby, 2014 .

Long-term outcome from the SCALOP trial: a multi-centre randomized phase II trial of gemcitabine or capecitabine-based chemoradiation (CRT) for locally advanced pancreatic cancer (LAPC)

R. Abrams, C. Hurt, J. Staffurth, 2016 .

A prospective phase II study of pre-operative chemotherapy then short-course radiotherapy for high risk rectal cancer: COPERNICUS

C. Hurt, P. Quirke, G. Griffiths, 2018, British Journal of Cancer.

Gut microbiology of UK care home residents: cross-sectional analysis from a randomised controlled trial.

P. Calder, K. Hood, M. Lown, 2023, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

NEOSCOPE: A randomised Phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine (OXCAP) or carboplatin/paclitaxel (CarPac) based chemoradiation (CRT) as pre-operative regimen for resectable oesophageal adenocarcinoma

H. Grabsch, C. Hurt, Ricky A. Sharma, 2016 .